Results 41 to 50 of about 342 (145)

Comparing the Efficacy and Safety of Nemolizumab Versus Anti-interleukin Monoclonal Antibody Therapies in Combination with Topical Treatments for Moderate-to-Severe Atopic Dermatitis Using Network Meta-analysis

Dermatology and Therapy
Introduction Atopic dermatitis (AD) is a complex disease with clinical heterogeneity. Nemolizumab is a novel interleukin (IL)-31 receptor alpha inhibitor that has demonstrated efficacy in managing moderate-to-severe AD. However, there are no head-to-head
Andrew E. Pink, John Houghton, Holly White, Sofia Schiavo, Christophe Piketty, Liliana Ulianov, Rajesh Rout, Katrin Jack, Ramkumar Subramanian, Jorge Puelles   +9 more
doaj   +1 more source

Swiss Practice Recommendations for Chronic Prurigo Including Prurigo Nodularis

International Journal of Dermatology, EarlyView.
Chronic prurigo, including prurigo nodularis, is a chronic, often treatment‐refractory condition characterized by persistent pruritus and chronic scratch lesions. Advances in the understanding of its underlying pathophysiology have enabled the development of novel targeted therapies; however, management remains challenging due to the expanding range of
Simon M. Mueller, Helmut Beltraminelli, Wolf‐Henning Boehncke, Maximilian Böhm, Antonio Cozzio, Peter Häusermann, Ahmad Jalili, Antonios G. A. Kolios, Claudia Lang, Eva Loos, Christoph Schlapbach, Curdin Conrad   +11 more
wiley   +1 more source

Scalp Dysesthesia: Emerging Pathophysiologic Insights and Therapeutic Implications

International Journal of Dermatology, EarlyView.
Scalp dysesthesia is a chronic condition diagnosed through exclusion. This scoping review synthesized data from 59 patients to identify recurrent clinical features, comorbidities, and management strategies that may support earlier diagnosis. Emerging patterns suggest that neuronal sensitization may underlie common symptoms.
Aditya K. Gupta, Jaspreet Kaur, Amanda Liddy, Paradi Mirmirani, Vincent Piguet   +4 more
wiley   +1 more source

Management of advanced mycosis fungoides and Sézary Syndrome: International Recommendations for systemic treatments and allogeneic hematopoietic cell transplantation from the European Hematology Association, the EORTC Cutaneous Lymphoma Tumours Group, the International Society for Cutaneous Lymphoma, and the Lymphoma Working Party of the EBMT

HemaSphere, Volume 10, Issue 11, November 2026.
Abstract Advanced mycosis fungoides (MF) and Sézary syndrome (SS) are the most aggressive forms of cutaneous T‐cell lymphoma and remain associated with a poor prognosis and heterogeneous therapeutic approaches. Recent advances, including targeted therapies and improved transplant strategies, have substantially expanded treatment options, highlighting ...
Francesco Onida, Pietro Quaglino, Julia Scarisbrick, Anna Sureda, Emmilia Hodak, Evangelia Papadavid, Silvia Alberti‐Violetti, Martine Bagot, Lorenzo Cerroni, Amrita Goyal‐O'Leary, Rudolf Stadler, Rein Willemze, Jasmine Zain, Marco Ardigò, Emilio Berti, Adèle de Masson, Rafael F. Duarte, Francine Foss, Eva González‐Barca, Joan Guitart, Pablo Ortiz‐Romero, Alessandro Pileri, Pierluigi Porcu, Henry M. Prince, Sima Rozati, Serena Rupoli, Maarten H. Vermeer, Sean Whittaker, Nicola Pimpinelli, Pier Luigi Zinzani   +29 more
wiley   +1 more source

Roles of Interleukin‐31 in Allergen‐Driven Cough: Linking Protease‐Activated Receptor‐2 Activation and Vagal Ganglion Sensitization in a Dermatophagoides farinae‐Induced Asthma Model

Brain and Behavior, Volume 16, Issue 9, September 2026.
In a Dermatophagoides farinae‐induced asthma model, IL‐31 deficiency did not substantially alter airway inflammation or immune responses but prevented the allergen‐induced enhancement of PAR‐2 expression and responsiveness in vagal sensory neurons.
Takayoshi Miyamoto, Chiharu Ohira, Mao Kaneki, Mariko Komuro, Mana Ichikawa, Ibuki Yasuda, Yoshiichi Takagi, Tomoki Fukuyama   +7 more
wiley   +1 more source

Machine-Learning-Based Prediction of Long-Term Efficacy of Nemolizumab: Post Hoc Analysis of Pooled Data from Two Phase III Clinical Trials

Dermatology and Therapy
Introduction Nemolizumab is a humanized monoclonal antibody that specifically inhibits the receptor for interleukin-31, the major pruritogen in atopic dermatitis (AD).
Makoto Kawashima, Tomoya Maeda, Kotaro Iwasaki, Masashi Takizawa, Noriaki Kaneda, Kenji Kabashima   +5 more
doaj   +1 more source

Comparative efficacy and safety of systemic therapies for moderate-to-severe atopic dermatitis in adults: a systematic review of randomized controlled trials

Frontiers in Immunology
BackgroundAtopic dermatitis (AD) is a common, chronic inflammatory skin condition, and patients with moderate-to-severe disease often require systemic therapy.
Vasiliki Pikoula, Vasiliki Pikoula, Efterpi Zafiriou, Anthony Bewley, Andrea Carugno, Ignasi Figueras Nart, Emily Kelly, Nina Magnolo, Julia-Tatjana Maul, Marta Szepietowska, Marta Szepietowska, Jacek C. Szepietowski, Jacek C. Szepietowski, Tiago Torres, Tiago Torres, Tiago Torres, Alexander Zink, Filomena Russo, Emanuele Scala, Maria-Angeliki Gkini   +19 more
doaj   +1 more source

Evidence Summary of Pruritus Management in Patients With Atopic Dermatitis: Implications for Nursing Practice

Journal of Cosmetic Dermatology, Volume 25, Issue 9, September 2026.
ABSTRACT Background To synthesize the most current and relevant evidence regarding pruritus management in patients with atopic dermatitis (AD), and to identify implications for nursing assessment, education, monitoring, and follow‐up. Method An extensive literature search was conducted across multiple databases, including the Cochrane Library, Embase ...
Yuzhen Shen, Qian Shen, Manni Chen, Rufang Liu   +3 more
wiley   +1 more source

Nemolizumab Versus Dupilumab in the Treatment of Prurigo Nodularis: Systematic Literature Review and Network Meta-analysis

Dermatology and Therapy
Prurigo nodularis (PN) is a chronic skin condition characterized by severe, persistent pruritus and impairment in health-related quality of life. Dupilumab and nemolizumab are the only treatments approved by the US Food and Drug Administration and the ...
Gil Yosipovitch, Katarzyna Borkowska, James Frampton, Kassandra Schaible, Marissa Betts, Katrin Jack, Zarif Jabbar Lopez, Binod Neupane, Christophe Piketty, Ramkumar Subramanian, Jorge Puelles Fernández de Trocóniz   +10 more
doaj   +1 more source

Update on biologic and small molecules treatments in pediatric allergic diseases

Pediatric Allergy and Immunology, Volume 37, Issue 9, September 2026.
This graphical abstract summarizes key targets, mechanisms of action, and indications of biologic and small molecules treatments in pediatric allergic diseases.abbreviations : BAS, basophil; BTK, Bruton tyrosine kinase; cDC, conventional dendritic cell; IgE, immunoglobulin E; FCER1, high affinity IgE receptor; IL, interleukin; IL4R, IL4 receptor; JAK ...
Herman T. den Dekker, Amandine Divaret Chauveau, Benoit Sterling, Stéphanie Coopman, R. Sharon Chinthrajah, Stéphanie Lejeune, Dorothea Holter, Thomas Eiwegger, Stéphanie Mallet, Mariëlle W. Pijnenburg, Antoine Deschildre   +10 more
wiley   +1 more source